SCPH SCPharmaceuticals Inc

scPharmaceuticals to Present at the Jefferies Healthcare Conference

scPharmaceuticals to Present at the Jefferies Healthcare Conference

BURLINGTON, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, is scheduled to present at the Jefferies Healthcare Conference, which is being held June 7-9 in New York.

Mr. Tucker’s presentation is scheduled for Wednesday, June 7, at 1:00 pm ET. Mr. Tucker will also be available to meet with investors on that day.

A live webcast of the presentation can be accessed under “News & Events” in the Investor Relations section of the Company’s website, .

About scPharmaceuticals

scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit .

Katherine Taudvin

scPharmaceuticals Inc., 781-301-6706

Investors:

PJ Kelleher

LifeSci Advisors, 617-430-7579



EN
31/05/2023

Underlying

SCPHSCPharmaceuticals Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SCPharmaceuticals Inc

 PRESS RELEASE
Free
SCPH SCPharmaceutica...

scPharmaceuticals Announces Participation in Three Upcoming Investor C...

scPharmaceuticals Announces Participation in Three Upcoming Investor Conferences BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President and Chief Executive Officer, will participate in the following upcoming investor conferences: The Citizens Life Sciences Conference: Presentation on Wednesday, May 7 at 9:30 a.m. ET.Craig-Hallum 22nd Annual Institutional Investor Conference: We...

May 1, 2025 1 EN
 PRESS RELEASE
Free
SCPH SCPharmaceutica...

scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Finan...

scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update scPharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024 U.S. Food and Drug Administration (FDA) approved the FUROSCIX expanded label indication to include the treatment of edema due to fluid overload in patients with chronic kidney disease scPharmaceuticals to host investor conference call and webcast today, Wednesday, March 19th,...

March 19, 2025 1 EN
 PRESS RELEASE
Free
SCPH SCPharmaceutica...

scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financ...

scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025 Management to host conference call and webcast, after-market on March 19, 2025, at 4:30 p.m. ET BURLINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, March 19, 2025, to discuss the financial results for ...

March 12, 2025 1 EN
 PRESS RELEASE
Free
SCPH SCPharmaceutica...

scPharmaceuticals Announces FDA Approval of Supplemental New Drug Appl...

scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease FDA approves scPharmaceuticals’ supplemental New Drug Application to expand the FUROSCIX indication to include the treatment of edema in adult patients with chronic kidney disease, including nephrotic syndrome FUROSCIX is expected to be available for chronic kidney disease patients in April 2025 BURLINGTON, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), ...

March 6, 2025 1 EN
 PRESS RELEASE
Free
SCPH SCPharmaceutica...

scPharmaceuticals Announces Participation in Two Upcoming Investor Con...

scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences BURLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President and Chief Executive Officer, will present at the following upcoming investor conferences: 45th Annual TD Cowen Healthcare Conference: Fireside chat on Wednesday, March 5 at 11:10AM ET.Leerink Partners 2025 Global Healthcare Conference: Corporate pre...

February 26, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch